Raymond James Financial
CYTK icon

Raymond James Financial’s Cytokinetics CYTK Stock Holding History

Raymond James Financial’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.52M Buy
88,259
+19,756
+29% +$1.42M ﹤0.01% 2395
2026
Q1 		$4.52M Sell
68,503
-13,892
-17% -$883K ﹤0.01% 2679
2025
Q4 		$5.24M Buy
82,395
+40,187
+95% +$2.5M ﹤0.01% 2479
2025
Q3 		$2.32M Buy
42,208
+36,759
+675% +$1.51M ﹤0.01% 3065
2025
Q2 		$180K Sell
5,449
-3,066
-36% -$107K ﹤0.01% 4566
2025
Q1 		$342K Buy
8,515
+3,115
+58% +$143K ﹤0.01% 4139
2024
Q4 		$254K Buy
+5,400
New +$280K ﹤0.01% 4279

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Raymond James Financial's CYTK Position: Q2 2026 in Review

Raymond James Financial increased its Cytokinetics (CYTK) stake by 29% in Q2 2026, buying an estimated $1.42M and bringing the position to 88,259 shares worth $7.52M. The position accounts for ﹤0.01% of the portfolio, ranked #2395.

Raymond James Financial first reported a position in CYTK in Q4 2024 and has held it in 7 quarters since. 483 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Raymond James Financial held 88,259 shares of Cytokinetics worth $7.52M as of Q2 2026.
  • Raymond James Financial bought 19,756 Cytokinetics shares in Q2 2026, an estimated $1.42M.
  • Cytokinetics made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #2395 holding.
  • Raymond James Financial first reported a position in Cytokinetics in Q4 2024 and has held it in 7 quarters since.
  • 483 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.